Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
| ▸ | GMNN | O75496 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | BLM | P54132 | 3/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcarnitine SCHEMBL13323920 | 1.00 | LMNA (0.96) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL3259109 | 1.00 | LMNA (0.96) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL2639482 | 0.98 | LMNA (1.00) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL28744378 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL4749513 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL3004012 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL2515409 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL29376874 | 0.98 | LMNA (1.00) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL20721036 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL27571008 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4595766-A1 | DIETARY SUPPLEMENT IN THE FORM OF A CHEWING GUM FOR A COMPLEX EFFECT ON APPETITE CONTROL, WEIGHT REDUCTION AND ENERGY INCREASE | Borisova-Dimitrova, Yoniela (BG) | 2025-08-06 | — | — | EP | claimed |
| CN-101796413-B | Method of determination of PDH activity and imaging media for use in said method | GE HEALTHCARE LTD | 2014-08-20 | — | — | CN | claimed |
| EP-4595766-A1 | DIETARY SUPPLEMENT IN THE FORM OF A CHEWING GUM FOR A COMPLEX EFFECT ON APPETITE CONTROL, WEIGHT REDUCTION AND ENERGY INCREASE | Borisova-Dimitrova, Yoniela (BG) | 2025-08-06 | — | — | EP | disclosed |
| CN-113866285-B | Biomarker for diabetes diagnosis and application thereof | 上海脉示生物技术有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20220211079-A1 | Omega-3 Beverage | LYNXIT SPORT NUTRITION AS (NO) | 2022-07-07 | — | — | US | disclosed |
| CN-113491688-A | Pharmaceutical composition for controlling blood sugar fluctuation | 常州高新技术产业开发区三维工业技术研究所有限公司 | 2021-10-12 | — | — | CN | disclosed |
| CN-113491686-A | Anti-stress pharmaceutical composition and application thereof | 常州高新技术产业开发区三维工业技术研究所有限公司 | 2021-10-12 | — | — | CN | disclosed |
| WO-2020225217-A1 | OMEGA-3 BEVERAGE | LYNXIT SPORT NUTRITION AS (NO) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020166674-A1 | COMPOSITION CONTAINING ORGANIC AMMONIUM SALT | ミヨシ油脂株式会社 | 2020-08-20 | — | — | WO | disclosed |
| US-20170231940-A1 | Multiparticulate L-Carnitine And Nootropic Compositions And Related Methods | Physician's Seal, LLC (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233725-A1 | Scavenger Compounds for Improved Sequencing-by-Synthesis | IsoPlexis Corporation | 2017-08-17 | — | — | US | disclosed |
| US-20100317890-A1 | L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same | SCIAN LABORATORIES, LLC (US) | 2010-12-16 | — | — | US | disclosed |
| CN-101883791-A | Humanized antibodies | GENENTECH INC | 2010-11-10 | — | — | CN | disclosed |
| US-20090312404-A1 | Cleavable Carnitine Compound | NOU LIFE SCIENCES, INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| CN-1665940-A | Diagnosis of sepsis using mitochondrial nucleic acid assays | UNIV BRITISH COLUMBIA (CA) | 2005-09-07 | — | — | CN | disclosed |
| CN-1162397-C | Therapeutically and/or nutritionaly enhanced derivatives of active ingredients and orally administrable compsns. contg. same | �����ι�˾ | 2004-08-18 | — | — | CN | disclosed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
| CN-1356976-A | Therapeutically and/or nutritionaly enhanced derivatives of active ingredients and orally administrable compsns. contg. same | BIOSALTS SRL (IT) | 2002-07-03 | — | — | CN | disclosed |
| EP-1082323-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca UK Limited (GB) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999064417-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312404-A1 | Cleavable Carnitine Compound | CPT1B, SLC25A20, CPT2 | LMNA 253/4885SMN1; SMN2 952/4885CYP1A2 1317/4885 |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | LMNA 3058/4885SMN1; SMN2 2401/4885CYP1A2 80/4885 |
| US-20100317890-A1 | L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same | CPT1A, CPT1B, SLC25A20 | LMNA 212/4885SMN1; SMN2 927/4885CYP1A2 2417/4885 |
| US-20170231940-A1 | Multiparticulate L-Carnitine And Nootropic Compositions And Related Methods | CPT1B, SLC25A20, CRAT | LMNA 785/4885SMN1; SMN2 584/4885CYP1A2 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.